Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 7/2006

01.10.2006 | ORIGINAL PAPER

(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population

verfasst von: Isabel Martínez-Gras, Janet Hoenicka, Guillermo Ponce, Roberto Rodríguez–Jiménez, Miguel Angel Jiménez-Arriero, Elena Pérez-Hernandez, Israel Ampuero, Jose Antonio Ramos-Atance, Tomas Palomo, Gabriel Rubio

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

The cannabinoid receptor 1 gene (CNR1) has been associated with addictive disorders and schizophrenia in different studies. We have compared the frequencies of the alleles for the 3′-UTR CNR1 microsatellite in a sample of 113 Spanish schizophrenic patients, including 68 with comorbid substance abuse, and 111 healthy controls. We report that the frequency of the allele 4 of this microsatellite is significantly lower in schizophrenia patients when compared with controls (χ2 = 7.858; df 1; = 0.005). No differences have been found with respect to substance abuse.
Thus, the allele 4 represents, in our sample, a protective factor against schizophrenia (odds ratio 0.468, 95% confidence interval (CI) 0.27–0.79). The population attributable genetic risk for the allele 4 absence is 30% (95% CI = 17–41%) and the attributable risk for the allele 4 absence in those with schizophrenia is 53% (95% CI = 20–73%). Our results suggest that, independent of substance abuse, differences in the cannabinoid system function could be involved in the vulnerability to schizophrenia in Spanish population.
Literatur
Zurück zum Zitat Abramson JH, Gahlinger PM (2001) Computer programs for epidemiologists: Pepi version 4.0. Sagebrush Press, Salt Lake City Abramson JH, Gahlinger PM (2001) Computer programs for epidemiologists: Pepi version 4.0. Sagebrush Press, Salt Lake City
Zurück zum Zitat Andreasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet ii: 1483–1486CrossRef Andreasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet ii: 1483–1486CrossRef
Zurück zum Zitat Arndt S, Tyrrell G, Flaum M, Andreasen N (1992) Comorbidity of substance abuse and schizophrenia. The role of pre-morbid adjustment. Psychol Med 22:379–388PubMedCrossRef Arndt S, Tyrrell G, Flaum M, Andreasen N (1992) Comorbidity of substance abuse and schizophrenia. The role of pre-morbid adjustment. Psychol Med 22:379–388PubMedCrossRef
Zurück zum Zitat Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Brit Med J 325:1212–1213PubMedCrossRef Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Brit Med J 325:1212–1213PubMedCrossRef
Zurück zum Zitat Arseneault L, Cannon M, Witton J, Murray R (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117PubMedCrossRef Arseneault L, Cannon M, Witton J, Murray R (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117PubMedCrossRef
Zurück zum Zitat Blackwell J, Beresfors J (1987) Cannabis self-medication and adverse reactions in psychyatric patients. Soc Pharmacol 1:357–358 Blackwell J, Beresfors J (1987) Cannabis self-medication and adverse reactions in psychyatric patients. Soc Pharmacol 1:357–358
Zurück zum Zitat Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127PubMedCrossRef Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127PubMedCrossRef
Zurück zum Zitat Caton C, Gralnick A, Bender S, Simon R (1989) Young chronic patients and substance abuse. Hosp Community Psychiatry 40:1037–1040PubMed Caton C, Gralnick A, Bender S, Simon R (1989) Young chronic patients and substance abuse. Hosp Community Psychiatry 40:1037–1040PubMed
Zurück zum Zitat Chaudry HR, Moss HB, Bashir A, Suliman T (1991) Cannabis psychosis following bhang ingestion. Br J Addict 86:1075–1081PubMedCrossRef Chaudry HR, Moss HB, Bashir A, Suliman T (1991) Cannabis psychosis following bhang ingestion. Br J Addict 86:1075–1081PubMedCrossRef
Zurück zum Zitat Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156–162PubMedCrossRef Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156–162PubMedCrossRef
Zurück zum Zitat Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G (1997) Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 2:161–168PubMedCrossRef Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G (1997) Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 2:161–168PubMedCrossRef
Zurück zum Zitat Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180:589–592PubMedCrossRef Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180:589–592PubMedCrossRef
Zurück zum Zitat Dawson E (1995) Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 5 (S50–S51):850 Dawson E (1995) Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 5 (S50–S51):850
Zurück zum Zitat Dean B, Sundram S, Bradbury R, Scarr E, Coplov D (2001) Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15PubMedCrossRef Dean B, Sundram S, Bradbury R, Scarr E, Coplov D (2001) Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15PubMedCrossRef
Zurück zum Zitat Drake RE, Wallack MA (1989) Substance abuse among the chronic mentally ill. Hosp Community Psychiatry 40:1041–1045PubMed Drake RE, Wallack MA (1989) Substance abuse among the chronic mentally ill. Hosp Community Psychiatry 40:1041–1045PubMed
Zurück zum Zitat Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMedCrossRef Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMedCrossRef
Zurück zum Zitat Firsts MB, Spitzer RL, Gibbon M, et al. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-IP, Version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute Firsts MB, Spitzer RL, Gibbon M, et al. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-IP, Version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute
Zurück zum Zitat Gardner EL (1992) Cannabinoid interaction with brain reward systems. The neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A (eds) Marijuana/cannabinnoids. Neurobiology and neurophysiology. CRC Press, Boca Raton, FL, pp 275–335 Gardner EL (1992) Cannabinoid interaction with brain reward systems. The neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A (eds) Marijuana/cannabinnoids. Neurobiology and neurophysiology. CRC Press, Boca Raton, FL, pp 275–335
Zurück zum Zitat Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162–165PubMed Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162–165PubMed
Zurück zum Zitat Hoehe MR, Caenazzo L, Martínez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14–q15. New Biol 3:880–885PubMed Hoehe MR, Caenazzo L, Martínez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14–q15. New Biol 3:880–885PubMed
Zurück zum Zitat Johnson JP, Muhleman D, Mc Murray J, Gade R, Verde R, Ask M, Kelley J, Comings DE (1997) Association between the cannaboind receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry 2:169–171PubMedCrossRef Johnson JP, Muhleman D, Mc Murray J, Gade R, Verde R, Ask M, Kelley J, Comings DE (1997) Association between the cannaboind receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry 2:169–171PubMedCrossRef
Zurück zum Zitat Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 15:401CrossRef Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 15:401CrossRef
Zurück zum Zitat Lehman AF, Myers CP, Dixon LB, Johnson JL (1994) Defining subgroups of dual diagnosis patitns for service planning. Hosp Community Psychiatry 45(6):556–561PubMed Lehman AF, Myers CP, Dixon LB, Johnson JL (1994) Defining subgroups of dual diagnosis patitns for service planning. Hosp Community Psychiatry 45(6):556–561PubMed
Zurück zum Zitat Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665–1669PubMed Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665–1669PubMed
Zurück zum Zitat Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM, Sham PC, Collier DA (2000) No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 5:128–130PubMedCrossRef Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM, Sham PC, Collier DA (2000) No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 5:128–130PubMedCrossRef
Zurück zum Zitat Linzsen DJ, Dingemans PM, Leniorm ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279 Linzsen DJ, Dingemans PM, Leniorm ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279
Zurück zum Zitat Mathers DC, Ghodse AH (1992) Cannabis and psychotic illness. Br J Psychiatry 161:648–653PubMed Mathers DC, Ghodse AH (1992) Cannabis and psychotic illness. Br J Psychiatry 161:648–653PubMed
Zurück zum Zitat McGuire PK, Jones P, Harvey L (1994) Cannabis and acute psychosis. Schizophr Res 13:161–167PubMedCrossRef McGuire PK, Jones P, Harvey L (1994) Cannabis and acute psychosis. Schizophr Res 13:161–167PubMedCrossRef
Zurück zum Zitat Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a review of etiological theories. Addict Behav 23(6):717–734PubMedCrossRef Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a review of etiological theories. Addict Behav 23(6):717–734PubMedCrossRef
Zurück zum Zitat Osher F, Kofoed L (1989) Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 40:1025–1030PubMed Osher F, Kofoed L (1989) Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 40:1025–1030PubMed
Zurück zum Zitat Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-Jiménez R, Palomo T, Ramos JA (2003) Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 8:466–467PubMedCrossRef Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-Jiménez R, Palomo T, Ramos JA (2003) Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 8:466–467PubMedCrossRef
Zurück zum Zitat Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A (2003) A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23:2453PubMed Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A (2003) A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23:2453PubMed
Zurück zum Zitat Rubio G (1999) Consumo de cannabis en diferentes grupos de población. In: Cabrera J (ed) Cannabis Hasta dondel Jornadas de expertos en cannabis en la Comunidad de Madrid, Comunidad de Madrid Agenica Antidrogal, pp 167–184 Rubio G (1999) Consumo de cannabis en diferentes grupos de población. In: Cabrera J (ed) Cannabis Hasta dondel Jornadas de expertos en cannabis en la Comunidad de Madrid, Comunidad de Madrid Agenica Antidrogal, pp 167–184
Zurück zum Zitat Rubio G, Casas M (2001) Revisión del tratamiento de la esquizofrenia en individuos con abuso de drogas. Act Esp Psiquiat 29:124–130 Rubio G, Casas M (2001) Revisión del tratamiento de la esquizofrenia en individuos con abuso de drogas. Act Esp Psiquiat 29:124–130
Zurück zum Zitat Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 175:641–652PubMedCrossRef Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 175:641–652PubMedCrossRef
Zurück zum Zitat Shearn C, Fitzgibbons D (1972) Patterns of dugs use in a population of youthful psychiatric patients. Am J Psychiatry 128:65–71 Shearn C, Fitzgibbons D (1972) Patterns of dugs use in a population of youthful psychiatric patients. Am J Psychiatry 128:65–71
Zurück zum Zitat Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR (2002) Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 65:221–224PubMedCrossRef Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR (2002) Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 65:221–224PubMedCrossRef
Zurück zum Zitat Test MA, Wallisch DJ, Allness D, Ripp K (1989) Substance use in young adults with schizophrenic disorders. Schizophrenia Bull 15:465–476 Test MA, Wallisch DJ, Allness D, Ripp K (1989) Substance use in young adults with schizophrenic disorders. Schizophrenia Bull 15:465–476
Zurück zum Zitat Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatric Genet 10:149–151CrossRef Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatric Genet 10:149–151CrossRef
Zurück zum Zitat Turner VM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophrenia Bull 16:87–95 Turner VM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophrenia Bull 16:87–95
Zurück zum Zitat Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515–518PubMedCrossRef Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515–518PubMedCrossRef
Zurück zum Zitat Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:19–27 Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:19–27
Zurück zum Zitat Weiser M, Knobler HY, Noy S, Kaplan Z (2002) Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114:949–955PubMedCrossRef Weiser M, Knobler HY, Noy S, Kaplan Z (2002) Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114:949–955PubMedCrossRef
Zurück zum Zitat Zammit S, Allebeck P, Andreasson S, Lundberg l, Lewis G (2002) Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Brit Med J 325:1199–1201PubMedCrossRef Zammit S, Allebeck P, Andreasson S, Lundberg l, Lewis G (2002) Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Brit Med J 325:1199–1201PubMedCrossRef
Zurück zum Zitat Zhang PW, Isighuro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR (2004) Human cannabinoid receptor 1:5’ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysusbstance abuse. Mol Psychiatry 9:916–931PubMedCrossRef Zhang PW, Isighuro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR (2004) Human cannabinoid receptor 1:5’ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysusbstance abuse. Mol Psychiatry 9:916–931PubMedCrossRef
Zurück zum Zitat Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulated cortex in schizophrenia. Pro. Neuropsychopharmacol Biol Psychiatry 28:355–360PubMedCrossRef Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulated cortex in schizophrenia. Pro. Neuropsychopharmacol Biol Psychiatry 28:355–360PubMedCrossRef
Zurück zum Zitat Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96(4):376–381PubMedCrossRef Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96(4):376–381PubMedCrossRef
Metadaten
Titel
(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population
verfasst von
Isabel Martínez-Gras
Janet Hoenicka
Guillermo Ponce
Roberto Rodríguez–Jiménez
Miguel Angel Jiménez-Arriero
Elena Pérez-Hernandez
Israel Ampuero
Jose Antonio Ramos-Atance
Tomas Palomo
Gabriel Rubio
Publikationsdatum
01.10.2006
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2006
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-006-0665-3

Weitere Artikel der Ausgabe 7/2006

European Archives of Psychiatry and Clinical Neuroscience 7/2006 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.